Mathieu Bilodeau

Université de Montréal, Montréal, Quebec, Canada

Are you Mathieu Bilodeau?

Claim your profile

Publications (2)4.79 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To assess the effect of duloxetine on ADHD in adults. Method: In a 6-week double-blind trial, 30 adults with ADHD received placebo or duloxetine 60 mg daily. The Conners' Adult ADHD Rating Scale (CAARS) and the Clinical Global Impression Scales (CGI) were used to assess symptom severity and clinical improvement. The Hamilton Anxiety Rating Scale (HARS) and the Hamilton Depression Rating Scale (HDRS) were used to measure the effect on anxiety and depressive symptoms. Results: The Duloxetine group showed lower score on CGI-Severity at Week 6 (3.00 vs. 4.07 for placebo, p < .001), greater improvement on CGI-Improvement (2.89 vs. 4.00 at Week 6, p < .001), and greater decreases on five of eight subscales of the CAARS. There was no treatment group effect on HDRS or HARS scores. Conclusion: Duloxetine may be a therapeutic option for adults with ADHD, but further studies are required to replicate these findings in larger samples. (J. of Att. Dis. 2012; XX(X) 1-XX).
    Journal of Attention Disorders 05/2012; 18(2). DOI:10.1177/1087054712443157
  • Smadar Valérie Tourjman, Mathieu Bilodeau
    [Show abstract] [Hide abstract]
    ABSTRACT: Attention-deficit/hyperactivity disorder (ADHD) is a common and disabling disorder among adults and is treated with stimulant and non stimulant medication. To report the case of a patient with ADHD showing good clinical response to duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI). A 53 year-old man with a recently diagnosed ADHD was successfully treated with duloxetine 60 mg and showed reduced scores on the Conners' Adult ADHD Rating Scales - Self-Report Scale: Short Version (CAARS-S:S). Duloxetine could be an option for patients who either do not tolerate or show resistance to more common pharmacological choices. Randomized controlled trials are needed to assess the efficacy of duloxetine in treating ADHD symptoms.
    Journal of Attention Disorders 05/2009; 13(1):95-6. DOI:10.1177/1087054708326109